FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163624251> ?p ?o ?g. }

• W3163624251 abstract "Abstract Importance COVID-19 has severely impacted older populations and strained healthcare resources, with many patients requiring long periods of hospitalization. Reducing the hospital length of stay (LOS) reduces patient and hospital burden. Given that adverse drug reactions are known to prolong LOS, unmanaged pharmacogenomic risk and drug interactions among COVID-19 patients may be a risk factor for longer hospital stays. Objective The objective of this study was to determine if pharmacogenomic and drug interaction risks were associated with longer lengths of stay among high-risk patients hospitalized with COVID-19. Design Retrospective cohort study of medical and pharmacy claims Setting Administrative database from a large U.S. health insurance company Participants Medicare Advantage members with a first COVID-19 hospitalization between January 2020 and June 2020, who did not die during the stay. Exposures (1) Pharmacogenetic interaction probability (PIP) of ≤25% (low), 26%–50% (moderate), or >50% (high), which indicate the likelihood that one or more clinically actionable gene-drug or gene-drug-drug interactions would be identified with testing; (2) drug-drug interaction (DDI) severity of minimal, minor, moderate, major, or contraindicated, which indicate the severity of an interaction between two or more active medications. Main Outcomes and Measures The primary outcome was hospital length of stay. Results were stratified by hierarchical condition categories (HCC) counts and chronic conditions. Results A total of 6,025 patients hospitalized with COVID-19 were included in the study. Patients with moderate or high PIP were hospitalized for 9% (CI: 4%–15%; p < 0.001) and 16% longer (CI: 8%–24%; p < 0.001), respectively, compared to those with low PIP, whereas RAF score was not associated with LOS. High PIP was significantly associated with 12%–22% longer lengths of stay compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or COPD. Finally, among patients with 2 or 3 HCCs, a 10% longer length of stay was observed among patients with moderate or more severe DDI compared to minimal or minor DDI. Conclusions and Relevance Proactively mitigating pharmacogenomic risk has the potential to reduce length of stay in patients hospitalized with COVID-19 especially those with COPD, diabetes, hyperlipidemia, and hypertension. Key Points Question What is the impact of unmanaged pharmacogenomic risk among patients hospitalized with COVID-19? Findings Among 6,025 patients hospitalized with COVID-19, those with greater unmanaged pharmacogenomic risk for adverse drug reactions had longer hospital stays than those with lower risk, both within the entire cohort and within groups matched by number and type of chronic conditions. Meaning Preemptive pharmacogenomic testing may shorten hospital stay by reducing adverse drug reactions among seriously ill patients and more broadly improve patient risk classification, care utilization predictions, and health system performance." @default.
• W3163624251 created "2021-05-24" @default.
• W3163624251 creator A5007477990 @default.
• W3163624251 creator A5015189970 @default.
• W3163624251 creator A5035495920 @default.
• W3163624251 creator A5039935740 @default.
• W3163624251 creator A5054837652 @default.
• W3163624251 creator A5055778428 @default.
• W3163624251 creator A5062211281 @default.
• W3163624251 creator A5062631136 @default.
• W3163624251 creator A5069326024 @default.
• W3163624251 creator A5070514085 @default.
• W3163624251 creator A5079160916 @default.
• W3163624251 date "2021-05-13" @default.
• W3163624251 modified "2023-10-17" @default.
• W3163624251 title "Pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare Advantage members with COVID-19" @default.
• W3163624251 cites W1969879564 @default.
• W3163624251 cites W2057738768 @default.
• W3163624251 cites W2073386434 @default.
• W3163624251 cites W2130736933 @default.
• W3163624251 cites W2132558113 @default.
• W3163624251 cites W2135046866 @default.
• W3163624251 cites W2144192049 @default.
• W3163624251 cites W2288260410 @default.
• W3163624251 cites W2521154593 @default.
• W3163624251 cites W2576620235 @default.
• W3163624251 cites W2792631875 @default.
• W3163624251 cites W2792968757 @default.
• W3163624251 cites W2809741215 @default.
• W3163624251 cites W2899608744 @default.
• W3163624251 cites W2935796977 @default.
• W3163624251 cites W2946209372 @default.
• W3163624251 cites W2948545777 @default.
• W3163624251 cites W3011508296 @default.
• W3163624251 cites W3011812737 @default.
• W3163624251 cites W3012268121 @default.
• W3163624251 cites W3038070845 @default.
• W3163624251 cites W3038939810 @default.
• W3163624251 cites W3057391939 @default.
• W3163624251 cites W3093570942 @default.
• W3163624251 cites W3097699764 @default.
• W3163624251 cites W3107523442 @default.
• W3163624251 cites W3108978936 @default.
• W3163624251 cites W3112171331 @default.
• W3163624251 cites W3129106200 @default.
• W3163624251 cites W3134480173 @default.
• W3163624251 cites W3136133007 @default.
• W3163624251 doi "https://doi.org/10.1101/2021.05.06.21256769" @default.
• W3163624251 hasPublicationYear "2021" @default.
• W3163624251 type Work @default.
• W3163624251 sameAs 3163624251 @default.
• W3163624251 citedByCount "1" @default.
• W3163624251 countsByYear W31636242512022 @default.
• W3163624251 crossrefType "posted-content" @default.
• W3163624251 hasAuthorship W3163624251A5007477990 @default.
• W3163624251 hasAuthorship W3163624251A5015189970 @default.
• W3163624251 hasAuthorship W3163624251A5035495920 @default.
• W3163624251 hasAuthorship W3163624251A5039935740 @default.
• W3163624251 hasAuthorship W3163624251A5054837652 @default.
• W3163624251 hasAuthorship W3163624251A5055778428 @default.
• W3163624251 hasAuthorship W3163624251A5062211281 @default.
• W3163624251 hasAuthorship W3163624251A5062631136 @default.
• W3163624251 hasAuthorship W3163624251A5069326024 @default.
• W3163624251 hasAuthorship W3163624251A5070514085 @default.
• W3163624251 hasAuthorship W3163624251A5079160916 @default.
• W3163624251 hasBestOaLocation W31636242511 @default.
• W3163624251 hasConcept C104863432 @default.
• W3163624251 hasConcept C126322002 @default.
• W3163624251 hasConcept C167135981 @default.
• W3163624251 hasConcept C170734499 @default.
• W3163624251 hasConcept C194828623 @default.
• W3163624251 hasConcept C197934379 @default.
• W3163624251 hasConcept C2779134260 @default.
• W3163624251 hasConcept C2780035454 @default.
• W3163624251 hasConcept C3008058167 @default.
• W3163624251 hasConcept C512399662 @default.
• W3163624251 hasConcept C524204448 @default.
• W3163624251 hasConcept C71924100 @default.
• W3163624251 hasConcept C98274493 @default.
• W3163624251 hasConceptScore W3163624251C104863432 @default.
• W3163624251 hasConceptScore W3163624251C126322002 @default.
• W3163624251 hasConceptScore W3163624251C167135981 @default.
• W3163624251 hasConceptScore W3163624251C170734499 @default.
• W3163624251 hasConceptScore W3163624251C194828623 @default.
• W3163624251 hasConceptScore W3163624251C197934379 @default.
• W3163624251 hasConceptScore W3163624251C2779134260 @default.
• W3163624251 hasConceptScore W3163624251C2780035454 @default.
• W3163624251 hasConceptScore W3163624251C3008058167 @default.
• W3163624251 hasConceptScore W3163624251C512399662 @default.
• W3163624251 hasConceptScore W3163624251C524204448 @default.
• W3163624251 hasConceptScore W3163624251C71924100 @default.
• W3163624251 hasConceptScore W3163624251C98274493 @default.
• W3163624251 hasLocation W31636242511 @default.
• W3163624251 hasLocation W31636242512 @default.
• W3163624251 hasOpenAccess W3163624251 @default.
• W3163624251 hasPrimaryLocation W31636242511 @default.
• W3163624251 hasRelatedWork W2030848629 @default.
• W3163624251 hasRelatedWork W2079759012 @default.
• W3163624251 hasRelatedWork W2101194650 @default.
• W3163624251 hasRelatedWork W2130261530 @default.

• next